EC grants drug orphan designation for CTCL

Micrograph showing
mycosis fungoides
The European Commission (EC) has granted orphan designation to MRG-106 for the treatment of cutaneous T-cell lymphoma (CTCL). MRG-106 is a locked nucleic acid-modified oligonucleotide inhibitor of miR-155-5p. miRagen Therapeutics, Inc., the company developing MRG-106, is currently testing the drug in a phase 1 trial of CTCL patients. Early... [Read Article]

Intensive chemo upfront means DHL patients can skip HSCT

Cancer patient receiving chemotherapy
Photo by Rhoda Baer
A new study suggests that patients with double-hit lymphoma (DHL) in first remission only benefit from an autologous hematopoietic stem cell transplant (auto-HSCT) if they received standard frontline chemotherapy. Researchers looked at long-term outcomes for DHL patients who achieved remission and, overall, found that auto-HSCT... [Read Article]

Drug receives fast track designation for follicular lymphoma

Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has granted fast track designation to the EZH2 inhibitor tazemetostat as a treatment for relapsed or refractory follicular lymphoma, with or without EZH2-activating mutations. The FDA’s fast track program is designed to facilitate the development and expedite the review of products intended... [Read Article]